Safety, pharmacokinetics and quantitative EEG modulation of TAK-071, a novel muscarinic M1 receptor positive allosteric modulator, in healthy subjects.
Saved in:
| Title: | Safety, pharmacokinetics and quantitative EEG modulation of TAK-071, a novel muscarinic M1 receptor positive allosteric modulator, in healthy subjects. |
|---|---|
| Authors: | Yin W; Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA., Mamashli F; Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.; Signal Insights, LLC, Cambridge, MA, USA., Buhl DL; Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA., Khudyakov P; Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA., Volfson D; Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA., Martenyi F; Prothena Biosciences, South San Francisco, CA, USA., Gevorkyan H; California Clinical Trials Medical Group, in affiliation with Parexel International, Glendale, CA, USA., Rosen L; Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA., Simen AA; Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA. |
| Source: | British journal of clinical pharmacology [Br J Clin Pharmacol] 2022 Feb; Vol. 88 (2), pp. 600-612. Date of Electronic Publication: 2021 Jul 31. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 7503323 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2125 (Electronic) Linking ISSN: 03065251 NLM ISO Abbreviation: Br J Clin Pharmacol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
